Seattle, WA -- (SBWIRE) -- 11/06/2019 -- Tacrolimus, also known as fujimycin or FK506, is an immunosuppressant drug that is used after organ transplant procedures to prevent organ rejection. The drug acts by obstructing the activation of serine-threonine phosphatase, calcineurin, in T lymphocytes. This in turn hinders activation of T lymphocyte and halts the production of cytotoxic lymphocytes that otherwise nay lead to organ rejection. Tacrolimus is used in kidney and liver transplant. Organ transplanted patients often rely on immunosuppressant therapy during their lifetime. Tacrolimus is used for the treatment of heart transplant rejection, liver transplant rejection, kidney transplant rejection, and lung transplant rejection. The drug can be administered in various dosage forms such as tablets, capsules, and injections.
Increasing technological advancements in organ transplant procedures is expected to aid in high adoption of the approach, thereby increasing demand for tacrolimus over the forecast period. Major institutes are focused on R&D of new methods to match more donor organs with patients. These activities include stem cell studies, trophic factor studies, and natural models. Increasing demand for organ transplant and its high unmet demand has led to focus on successful utilization and transplantation of available donor organs.
Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2298
For instance, according to Organ Procurement and Transplantation Network (OPTN) 117,000+ number of men, women, and children are on the national transplant waiting list as of July 2017 in the U.S. and 17,155 organ transplants are done so far in 2017. Moreover, according to National Kidney Foundation as of 2016, 121,678 people are waiting for lifesaving organ transplants in the U.S., of which 100,791 people are waiting for kidney transplants.
Better understanding of immunology has increased matching rates for organs and patients after transplants, which also helps in high adoption of organ transplant, thereby aiding the global tacrolimus market growth over the forecast period.
However, significant gap between demand and supply of transplant organs is a major factor hampering growth of the global tacrolimus market. Use of tacrolimus is also associated with certain side effects such ad malignancy, Psychosis, and others, which is expected to hinder the market growth to some extent.
Get Request Sample from Industry Experts @ https://www.coherentmarketinsights.com/insight/request-sample/2298
On the basis of region, the global tacrolimus market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The market in North America is expected to hold dominant position over the forecast period, owing to high presence of major market players and increasing number of organ transplant procedures. Key players in the market are focused on developing generic version of tacrolimus. For instance, Strides Arcolab received the U.S. Food & Drug Administration (FDA) approval for tacrolimus capsules to be used as immuno-suppressant in 2014. Sandoz launched Tacrolimus, a generic version of Astellas's PROGRAF (tacrolimus) in Japan, in 2015. Moreover, The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended granting marketing authorization for tacrolimus' generic, Tacforius in 2017.
Major players operating in the global tacrolimus market include, GlaxoSmithKline Plc., Takeda Pharmaceuticals Company Ltd., Abbott Laboratories, Novartis International AG, Mylan N.V., Astellas Pharma, Inc., Senju Pharmaceutical Co. Ltd., Guike Pharmaceutical Co. Ltd., DR. Reddy's Laboratories Ltd., and Glenmark Pharmaceuticals Ltd.
Inquire about Discount on this Report @ https://www.coherentmarketinsights.com/insight/request-discount/2298
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.